ISDS Case Map
intellectual property
The gains accruing to the Indian generic drugs industry as a result of the Supreme Court judgement on the Novartis case may be lost if India accepts demands by the European Union (EU) under the proposed free trade agreement (FTA) between the two sides.
Negotiating text on intellectual property for the EU-India FTA. It does not include Article 6 (patents) or have any text for Article 9 (GIs). Date unknown.
Drugmakers and healthcare activists are worried that the India-European Union Free Trade Agreement (FTA), which is in the works, may contain a provision that could imperil local industry and have urged the government to keep patent infringement issues out of FTAs.
A French company’s attempt to claim "rooibos" as its own intellectual property has galvanised the South African government into action to protect the term under its talks with Brussels over the EU-South Africa EPA.
India's largest dairy co-operative - Amul - has requested the commerce ministry to relook at the EU-India Free Trade Agreement.
The FTA might enable seizure of property of generic drug makers on suspicion of IP rights infringement
A comparison of language between two of the most substantive and recent free trade agreements (FTAs) adopted by the US and the EU for one controversial area of IP: liability for internet service providers (ISP) for infringing content.
The free trade agreement that European Union is pushing India to sign could put an end to India's status as the pharmacy of the developing providing affordable medicines, especially HIV drugs to countries like Brazil, Thailand, South Africa, Zimbabwe and several others. The negotiations with EU are on at a feverish pace this week in Brussels even before the parliamentary standing committee looking into the free trade agreements (FTAs) has submitted its report.
"From a democratic perspective, we believe that important rules governing technology, health, and culture should be debated in the US Congress, the European Parliament, national parliaments, and other transparent forums where all stakeholders can be heard—not in closed negotiations that give privileged access to corporate insiders."
The TPP negotiators are making decisions that will affect at least 600 million people, and potentially hundreds of millions more, in complete secrecy, and this is unacceptable.
